• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于特异性和敏感性未知的检测对疾病患病率进行精确推断。

Exact inference for disease prevalence based on a test with unknown specificity and sensitivity.

作者信息

Cai Bryan, Ioannidis John P A, Bendavid Eran, Tian Lu

机构信息

Department of Computer Science, Stanford University, Stanford, CA, USA.

Department of Medicine, Stanford University, Stanford, CA, USA.

出版信息

J Appl Stat. 2022 Jan 4;50(11-12):2599-2623. doi: 10.1080/02664763.2021.2019687. eCollection 2023.

DOI:10.1080/02664763.2021.2019687
PMID:37529562
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10388830/
Abstract

To make informative public policy decisions in battling the ongoing COVID-19 pandemic, it is important to know the disease prevalence in a population. There are two intertwined difficulties in estimating this prevalence based on testing results from a group of subjects. First, the test is prone to measurement error with unknown sensitivity and specificity. Second, the prevalence tends to be low at the initial stage of the pandemic and we may not be able to determine if a positive test result is a false positive due to the imperfect test specificity. The statistical inference based on a large sample approximation or conventional bootstrap may not be valid in such cases. In this paper, we have proposed a set of confidence intervals, whose validity doesn't depend on the sample size in the unweighted setting. For the weighted setting, the proposed inference is equivalent to hybrid bootstrap methods, whose performance is also more robust than those based on asymptotic approximations. The methods are used to reanalyze data from a study investigating the antibody prevalence in Santa Clara County, California in addition to several other seroprevalence studies. Simulation studies have been conducted to examine the finite-sample performance of the proposed method.

摘要

为了在抗击持续的新冠疫情中做出明智的公共政策决策,了解人群中的疾病流行率很重要。基于一组受试者的检测结果来估计这种流行率存在两个相互交织的困难。首先,该检测容易出现测量误差,其灵敏度和特异性未知。其次,在疫情初期流行率往往较低,由于检测特异性不完善,我们可能无法确定阳性检测结果是否为假阳性。在这种情况下,基于大样本近似或传统自助法的统计推断可能无效。在本文中,我们提出了一组置信区间,其有效性在未加权设置下不依赖于样本量。对于加权设置,所提出的推断等同于混合自助法,其性能也比基于渐近近似的方法更稳健。这些方法除了用于重新分析其他几项血清流行率研究的数据外,还用于重新分析一项调查加利福尼亚州圣克拉拉县抗体流行率的研究数据。已进行模拟研究以检验所提方法的有限样本性能。

相似文献

1
Exact inference for disease prevalence based on a test with unknown specificity and sensitivity.基于特异性和敏感性未知的检测对疾病患病率进行精确推断。
J Appl Stat. 2022 Jan 4;50(11-12):2599-2623. doi: 10.1080/02664763.2021.2019687. eCollection 2023.
2
Effectiveness and cost-effectiveness of four different strategies for SARS-CoV-2 surveillance in the general population (CoV-Surv Study): a structured summary of a study protocol for a cluster-randomised, two-factorial controlled trial.在普通人群中进行 SARS-CoV-2 监测的四种不同策略的有效性和成本效益(CoV-Surv 研究):一项关于集群随机、双因素对照试验的研究方案的结构化总结。
Trials. 2021 Jan 8;22(1):39. doi: 10.1186/s13063-020-04982-z.
3
Estimation of Covid-19 prevalence from serology tests: A partial identification approach.通过血清学检测估计新冠病毒病的流行率:一种部分识别方法。
J Econom. 2021 Jan;220(1):193-213. doi: 10.1016/j.jeconom.2020.10.005. Epub 2020 Oct 20.
4
The risk of over-diagnosis in serological testing. Implications for communications strategies.血清学检测的过度诊断风险。对沟通策略的影响。
Epidemiol Prev. 2020 Sep-Dec;44(5-6 Suppl 2):184-192. doi: 10.19191/EP20.5-6.S2.117.
5
Enhanced Inference for Finite Population Sampling-Based Prevalence Estimation with Misclassification Errors.基于有限总体抽样且存在错误分类误差情况下患病率估计的增强推断
Am Stat. 2024;78(2):192-198. doi: 10.1080/00031305.2023.2250401. Epub 2023 Sep 21.
6
Exact confidence limits for prevalence of a disease with an imperfect diagnostic test.诊断试验不完美时疾病流行率的确切置信限。
Epidemiol Infect. 2010 Nov;138(11):1674-8. doi: 10.1017/S0950268810000385. Epub 2010 Mar 3.
7
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
8
Rapid Sentinel Surveillance for COVID-19 - Santa Clara County, California, March 2020.COVID-19 快速监测 - 加利福尼亚州圣克拉拉县,2020 年 3 月。
MMWR Morb Mortal Wkly Rep. 2020 Apr 10;69(14):419-421. doi: 10.15585/mmwr.mm6914e3.
9
Efficient statistical inference for a parallel study with missing data by using an exact method.使用精确方法对具有缺失数据的平行研究进行有效统计推断。
J Biopharm Stat. 2019;29(3):478-490. doi: 10.1080/10543406.2019.1605782. Epub 2019 Apr 24.
10
Improved confidence intervals of a small probability from pooled testing with misclassification.基于合并检测的错误分类的小概率的置信区间的改进。
Front Public Health. 2013 Oct 7;1:39. doi: 10.3389/fpubh.2013.00039. eCollection 2013.

引用本文的文献

1
Editorial to the special issue: statistical perspectives on analytics for COVID-19 data.特刊社论:关于COVID-19数据分析的统计学视角
J Appl Stat. 2023 Jul 28;50(11-12):2287-2293. doi: 10.1080/02664763.2023.2228597. eCollection 2023.
2
Estimation of SARS-CoV-2 Seroprevalence in Central North Carolina: Accounting for Outcome Misclassification in Complex Sample Designs.北卡罗来纳州中部估计 SARS-CoV-2 血清流行率:在复杂样本设计中考虑结果的错误分类。
Epidemiology. 2023 Sep 1;34(5):721-731. doi: 10.1097/EDE.0000000000001625. Epub 2023 Jul 31.
3
Confidence intervals for prevalence estimates from complex surveys with imperfect assays.复杂调查中存在不完美检测时的患病率估计的置信区间。
Stat Med. 2023 May 20;42(11):1822-1867. doi: 10.1002/sim.9701. Epub 2023 Mar 3.
4
Machine learning for optimal test admission in the presence of resource constraints.资源约束下的最优测试纳入的机器学习方法。
Health Care Manag Sci. 2023 Jun;26(2):279-300. doi: 10.1007/s10729-022-09624-1. Epub 2023 Jan 12.
5
Reconciling estimates of global spread and infection fatality rates of COVID-19: An overview of systematic evaluations.协调全球 COVID-19 传播和感染病死率的估计值:系统评价概述。
Eur J Clin Invest. 2021 May;51(5):e13554. doi: 10.1111/eci.13554. Epub 2021 Apr 9.

本文引用的文献

1
Infection fatality rate of COVID-19 inferred from seroprevalence data.基于血清流行率数据推断的 COVID-19 感染病死率。
Bull World Health Organ. 2021 Jan 1;99(1):19-33F. doi: 10.2471/BLT.20.265892. Epub 2020 Oct 14.
2
COVID-19 antibody seroprevalence in Santa Clara County, California.加利福尼亚州圣克拉拉县的新冠病毒抗体血清流行率。
Int J Epidemiol. 2021 May 17;50(2):410-419. doi: 10.1093/ije/dyab010.
3
Estimation of SARS-CoV-2 Infection Fatality Rate by Real-time Antibody Screening of Blood Donors.通过实时献血者抗体筛查估计 SARS-CoV-2 感染病死率。
Clin Infect Dis. 2021 Jan 27;72(2):249-253. doi: 10.1093/cid/ciaa849.
4
SARS-CoV-2 antibody prevalence in Brazil: results from two successive nationwide serological household surveys.巴西的 SARS-CoV-2 抗体流行率:两项连续全国血清学家庭调查结果。
Lancet Glob Health. 2020 Nov;8(11):e1390-e1398. doi: 10.1016/S2214-109X(20)30387-9. Epub 2020 Sep 23.
5
SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood.SARS-CoV-2 血清阳性率及中和活性在供者和患者血液中的变化。
Nat Commun. 2020 Sep 17;11(1):4698. doi: 10.1038/s41467-020-18468-8.
6
Adjusting Coronavirus Prevalence Estimates for Laboratory Test Kit Error.调整冠状病毒流行率估计值以消除实验室检测试剂盒误差。
Am J Epidemiol. 2021 Jan 4;190(1):109-115. doi: 10.1093/aje/kwaa174.
7
Epidemiological and clinical characteristics of the COVID-19 epidemic in Brazil.巴西 COVID-19 疫情的流行病学和临床特征。
Nat Hum Behav. 2020 Aug;4(8):856-865. doi: 10.1038/s41562-020-0928-4. Epub 2020 Jul 31.
8
Seroprevalence of SARS-CoV-2-Specific Antibodies, Faroe Islands.血清新型冠状病毒特异性抗体阳性率,法罗群岛。
Emerg Infect Dis. 2020 Nov;26(11):2761-2763. doi: 10.3201/eid2611.202736. Epub 2020 Jul 29.
9
Seroprevalence of Antibodies to SARS-CoV-2 in 10 Sites in the United States, March 23-May 12, 2020.2020年3月23日至5月12日美国10个地点针对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)抗体的血清流行率
JAMA Intern Med. 2020 Jul 21. doi: 10.1001/jamainternmed.2020.4130.
10
Estimation of COVID-19 prevalence in Italy, Spain, and France.估算意大利、西班牙和法国的 COVID-19 流行率。
Sci Total Environ. 2020 Aug 10;729:138817. doi: 10.1016/j.scitotenv.2020.138817. Epub 2020 Apr 22.